SCHEMBL2578296

SCHEMBL2578296

Cn1c(=O)c(C(=O)NCC(=O)OC(C)(C)C)c(O)c2cc(C3CCCO3)c(C(F)(F)F)nc21

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GAA P10253 1/20 0.37
HIF1A Q16665 12/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
EGLN1 Q9GZT9 3/20 0.35
EGLN2 Q96KS0 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.35
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12154801 1.00 KDM4E (0.42) KDM4ERAB9AKMT2ASMN1; SMN2GAA
SCHEMBL2578294 1.00 KDM4E (0.42) KDM4ERAB9AKMT2ASMN1; SMN2GAA
SCHEMBL2578868 1.00 KDM4E (0.42) KDM4ERAB9AKMT2ASMN1; SMN2GAA
SCHEMBL2576970 0.90 EGLN1 (0.44) KDM4ERAB9AKMT2ASMN1; SMN2HIF1A
SCHEMBL2576902 0.90 EGLN1 (0.44) KDM4ERAB9AKMT2ASMN1; SMN2HIF1A
SCHEMBL2576398 0.90 EGLN1 (0.44) KDM4ERAB9AKMT2ASMN1; SMN2HIF1A
SCHEMBL2581065 0.88 HIF1A (0.38) KDM4ERAB9AKMT2ASMN1; SMN2GAA
SCHEMBL12101621 0.88 HIF1A (0.39) HIF1AEGLN1
SCHEMBL2581087 0.87 HIF1A (0.37) KDM4ERAB9AKMT2ASMN1; SMN2GAA
SCHEMBL2578890 0.86 HIF1A (0.36) KDM4ERAB9AKMT2ASMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 EP disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN KDM4E 99/4885RAB9A 4344/4885KMT2A 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.